CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Zr89-trastuzumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01420146
NCT01420146Phase 1Completed
CompareCT.gov

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients : Correlation With FDG-PET/CT and Anatomopathological Results

Jules Bordet Institute·interventional·Posted Aug 19, 2011·Updated Apr 18, 2017

In Brief

A Phase 1 clinical trial evaluating Zr89-trastuzumab for Breast Neoplasms and 2 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms, Secondary, HER2 Positive Carcinoma of Breast
CountriesBelgium
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 19, 2011
Enrollment StartAug 1, 2011
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 14.9 years ago

Interventions

Zr89-trastuzumabdrug

trastuzumab labelled with zirconium 89 for PET/CT